Related Experiment Video
Updated: Sep 11, 2025
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or
Riccardo Gili1, Patrizia Morbini2, Paolo Bossi3
1UO Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.
Abstract:
The Combined Positive Score (CPS) currently represents the sole biomarker employed in clinical practice to predict the efficacy of immune checkpoint inhibitors (ICIs) and to guide optimal personalized treatment sequencing in head and neck squamous cell carcinoma (HNSCC). However, CPS alone is insufficient for accurate patient stratification and prediction of ICI response, necessitating integration with additional immune-related biomarkers. The spatial distribution of programmed death ligand-1 (PD-L1) expressing cells may offer a promising approach to more comprehensively characterize both the tumor microenvironment (TME) and malignant cells, elucidate their interactions, and enhance the predictive value regarding response to ICI therapy.This perspective aims to investigate the potential role of spatial assessment of PD-L1 expression in improving patient stratification and therapeutic outcomes in HNSCC.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018